In recent weeks, the FDA has issued three approvals for ophthalmic indications and multiple other rulings regarding ophthalmic drugs and technology.
Here is the most recent FDA-related ophthalmology news as reported on Healio.com/OSN:
FDA approves Luxturna for inherited retinal dystrophy
The FDA announced the approval of Luxturna to treat children and adult patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Read more.
Aerie Pharmaceuticals announces FDA approval of Rhopressa
Rhopressa (netarsudil ophthalmic solution 0.02%) is a once-daily eye drop designed
Uncategorized